Recently developed ASAH1 inhibitors (e.g., N-oleoylethanolamine, B13, and benzoxazolone carboxamides) have been defined as chemosensitizers that can be combined with conventional chemo- and radiotherapies against human glioma and other (prostate and L929) tumor cells in vitro, as well as in xenograft models [137,184]. Here, ASAH1 is linked to central nervous system cancer.